Niagen Bioscience has announced that Nicotinamide Riboside Chloride (NRCl) now has a published United States Pharmacopeia (USP) dietary supplement ingredient monograph.
NRCl is the patented form of nicotinamide riboside in the company’s flagship ingredient, Niagen.
The monograph makes NR the first among NR, NMN and NAD+ to receive a pharmacopeial quality benchmark, setting a global standard for what high-quality NRCl should look like in dietary supplements and limiting the presence of adulterants and contaminants.
Rob Fried, CEO of Niagen Bioscience, said: “This monograph is a meaningful development for the broader NAD+ supplement industry because NR now has a published pharmacopeial standard, while NMN and NAD+ do not.”
It underscores the importance of doing the long-term scientific and technical work required to help define a quality standard.
The USP is an independent nonprofit that sets quality standards for medicines, food ingredients and dietary supplements.
The US Food and Drug Administration (FDA) and international regulators use USP standards to evaluate the purity, potency, identity and testing methods of these products.
Aron Erickson, Vice President, Research and Development at Niagen Bioscience, commented: “The monograph for NRCl is based on the scientific data, analytical methods and specifications that we established for Niagen.”
Niagen Bioscience worked with USP for six years as the sponsor of the monograph initiative, contributing methods and specifications that established the NRCl standard.
The published monograph specifies quality requirements for NRCl, including identity testing, assay specifications, impurity limits and packaging requirements.
It will be available in USP’s compendium and is expected to be codified and enforced in October 2026.
